TCGA-GU-AATQ-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6.997371879
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- MYC_TARGETS_V1+0.490
- G2M_CHECKPOINT+0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.480
- E2F_TARGETS+0.470
- MTORC1_SIGNALING+0.380
- DNA_REPAIR+0.290
- OXIDATIVE_PHOSPHORYLATION+0.280
- PI3K_AKT_MTOR_SIGNALING+0.270
- CHOLESTEROL_HOMEOSTASIS+0.240
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.390
- TGF_BETA_SIGNALING-0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- HEDGEHOG_SIGNALING-0.240
- APOPTOSIS-0.210
- IL2_STAT5_SIGNALING-0.200
- INFLAMMATORY_RESPONSE-0.200
- KRAS_SIGNALING_UP-0.180
- COMPLEMENT-0.170
- ALLOGRAFT_REJECTION-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03204 | — | cohortSQ2 | 0.879 |
| 2 | MNG358 | — | — | 0.869 |
| 3 | SRR6013575 | — | cohortSQ2 | 0.862 |
| 4 | TCGA-85-8277-01A-11R-2296-07 | — | cohortSQ2 | 0.855 |
| 5 | fddf611e-f586-49e1-9ee8-8ac853accb9e | — | — | 0.852 |
| 6 | TCGA-66-2727-01A-01R-0980-07 | — | cohortSQ2 | 0.851 |
| 7 | TCGA-A8-A092-01A-11R-A00Z-07 | — | B | 0.846 |
| 8 | TCGA-NC-A5HN-01A-11R-A26W-07 | — | cohortSQ2 | 0.837 |
| 9 | SRR8518230 | — | E | 0.836 |
| 10 | SRR8613729 | — | E | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |